Deletion of miR‐33, a regulator of the ABCA1–APOE pathway, ameliorates neuropathological phenotypes in APP/PS1 mice
Tate M, Wijeratne H, Kim B, Philtjens S, You Y, Lee D, Gutierrez D, Sharify D, Wells M, Perez‐Cardelo M, Doud E, Fernandez‐Hernando C, Lasagna‐Reeves C, Mosley A, Kim J. Deletion of miR‐33, a regulator of the ABCA1–APOE pathway, ameliorates neuropathological phenotypes in APP/PS1 mice. Alzheimer's & Dementia 2024, 20: 7805-7818. PMID: 39345217, DOI: 10.1002/alz.14243.Peer-Reviewed Original ResearchAmyloid-betaAlzheimer's diseaseMicroglial migrationAmyloid mouse modelMiR-33Multi-omics studiesABCA1 levelsPotential drug targetsIncreased ABCA1 protein levelsMicroRNA-33ApoE lipidationProteomic changesRNA sequencingMulti-omicsNeuropathological phenotypeAmyloid pathologyInhibition of miR-33APP/PS1 micePhagocytosis in vitroRare variantsApolipoprotein EDrug targetsABCA1 protein levelsAmyloidPlaque deposition